WO1997011186A1 - Verfahren zur herstellung von natriuretischen peptiden über streptavidin-fusionsproteine - Google Patents
Verfahren zur herstellung von natriuretischen peptiden über streptavidin-fusionsproteine Download PDFInfo
- Publication number
- WO1997011186A1 WO1997011186A1 PCT/EP1996/004061 EP9604061W WO9711186A1 WO 1997011186 A1 WO1997011186 A1 WO 1997011186A1 EP 9604061 W EP9604061 W EP 9604061W WO 9711186 A1 WO9711186 A1 WO 9711186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fusion protein
- peptide
- protein
- amino acids
- streptavidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the invention relates to a process for the recombinant production of natriuretic peptides (NP peptides) by expression of streptavidin fusion proteins and subsequent cleavage of the fusion proteins with a suitable restriction endoprotease.
- NP peptides natriuretic peptides
- Natriuretic peptides are peptides with natriuretic activity which are formed in the cardiac ventricle, the adrenal gland and the brain from a precursor polypeptide (prohormone) and which have a ring of 17 amino acids as a structural element which is separated by a disulfide bend between two Cysteine residues is formed.
- Precursor polypeptides are e.g. B the "atrial” natriuretic peptide (ANP 1-126) or cardiodilatin (CCD 1-126) and the "brain" natriuretic peptides of the B and C type
- Urodilatin (CDD 95-126) is a natriuretic peptide which can be obtained from human urine (Forssmann, K. et al, Clin. Klisch. 66 (1988) 752-759 (20).
- the peptide has a length of 32 amino acids, forms a ring of 17 amino acids through the formation of a disulfide bridge between two cysteine residues and belongs to the Cardio ⁇ dilatin / "atrial" -natriuretic peptide (CDD / ANP) family.
- Urodilatin Like ⁇ -ANP (99 - 126), from the ANP propeptide (ANP 1-126) Urodilatin (CCD 95-126) is probably produced in vivo by cleavage of this propeptide between amino acids 94 and 95.
- the approximately 3.5 kDa urodilatin peptide differs ⁇ -ANP (99-126) peptide by a 4-amino acid extension at the N-terminus
- the amino acid sequence and the structure of urodilatin are described, for example, in Drummer, C et al., Pflugers Archiv, European J. of Physiol.
- Urodilatin binds to the membrane-bound ANP receptors A and B and activates an intracellular guanylate cyclase coupled to the receptor. This causes the formation of the "second messenger" cGMP, which mediates the diuretic and natriuretic effects in the kidney and the relaxing effect on the smooth vascular muscles. (Heim, JM, Biochem. Biophys. Res. Commun. 163 (1989) 37-41 (22)). Urodilatin is thus a preferred therapeutic agent for the prophylaxis and therapy of acute kidney failure, e.g. B. in patients after heart or liver transplants (Bub, A. et al., Histochem. J.
- propeptide of ⁇ -ANP (99-126) or urodilatin is usually carried out by chemical peptide synthesis (Kent, SBH et al., Banburi Rep. 29 (1988) 3-20 (1); Hodson, JH, Bio / Technology 11 (1993) 1309-1310 (2)).
- soluble fusion proteins with a selective cleavage sequence and subsequent release of the desired peptide by chemical or enzymatic cleavage (Sharma, A. et al., Proc. Natl. Acad. Sei. USA 91 (1994) 9337 - 9341 (29); Gram, H., Bio / Technology 12 (1994) 1017-1023) (30).
- the disadvantage of soluble fusion proteins is in particular that they can be degraded in the unstructured peptide region by proteolysis already in the cell or during secretion and processing.
- streptavidin fusion proteins The production of streptavidin fusion proteins is described in Sano, T. et al., Biochem. Biophys. Res. Commun. 176 (1991) 571-577 (9) and Sano, T. et al., Proc. Natl. Acad. Sei., USA 89 (1992) 1534-1538 (10).
- the chimeric protein comprises, as streptavidin portion, the amino acids 16-133 of streptavidin, a polylinker and the sequence of the "target protein".
- Sano describes the mouse metallothionein I protein and the T7 gene 10 protein as target proteins. However, these chimeric proteins did not contain a cleavage site via which the "target protein" can be cleaved off from the streptavidin portion.
- the object of the present invention is to provide a method by which NP peptides, preferably C-terminal ANP (1-126) peptide fragments (amino acids (AS) 1 - 126), how the fragments AS 95 - 126 (urodilatin), AS 99 - 126 ( ⁇ -ANP) or AS 102 - 126 can be produced in high yield and purity.
- NP peptides preferably C-terminal ANP (1-126) peptide fragments (amino acids (AS) 1 - 126), how the fragments AS 95 - 126 (urodilatin), AS 99 - 126 ( ⁇ -ANP) or AS 102 - 126 can be produced in high yield and purity.
- the object is achieved according to the invention by a method for the recombinant production of an NP peptide by expression of a DNA in prokaryotes, which is used for a fusion protein from streptavidin, which is C-terminal with the N-terminus of the said NP peptide via a peptide sequence (hereinafter also referred to as linker), which contains at least one lysine at the C-terminus and is cleavable by endoproteinase LysC, is coded, isolation of the insoluble, inactive protein, solubilization of the inactive protein, cleavage of the fusion protein with endoproteinase LysC and isolation of the desired one NP peptide.
- linker a peptide sequence
- endoproteinase LysC cleaves the fusion proteins according to the invention completely, although it is known that endoproteinase LysC cleaves fusion proteins usually only very ineffectively (Allen, G. et al., J. Cell. Sei. Suppl. 3 (1985) 29-38) (40) .
- endoproteinase LysC essentially cleaves the fusion protein only on the lysine of the linker. This is particularly surprising since it would have been expected that endoproteinase LysC would also cleave at the 4 lysine residues of the streptavidin portion of the fusion protein. Since the cleavage is also fast and practically complete, the combination of streptavidin fusion protein and cleavage with endoproteinase LysC represents a particularly suitable system for the recombinant production of urodilatin.
- Endoproteinase LysC is an endoproteinase that specifically cleaves proteins and peptides at the C-terminal end of lysine.
- Such an enzyme is known, for example, from fungi or bacteria (DE 30 34 045 C2).
- Endoproteinase LysC from bacteria is a protein with a molecular weight of 35 - 38 kDa.
- the pH optimum is 7.7 and the enzyme is inhibited by aprotinin.
- the specific activity, measured with tosyl-glycyl-prolyl-lysyl-p-nitroaniline at 25 ° C, is approx. 25 U / mg or approx. 50 Azocoll® units / mg enzyme at 37 ° C.
- the enzyme can be isolated and purified, for example, from the Lysobacteraceae culture broth.
- Endoproteinase-LysC (EC 3.4.21.50) from Lysobacter Enzymogenes is available from Boehringer Mannheim GmbH, Germany, Order No. 476986.
- Endoproteinase LysC is used to cleave fusion proteins that do not contain lysine residues (Ladisch, MR (Editor) Protein Purification ACS-Symposium, Series 427, American Chemical Society, Washington DC 1990, 189 (31); Allen, G. et al., J. Cell. Sci. Suppl. 3 (1985) 29 (32)).
- a linker in the sense of the present invention, is to be understood as a short-chain peptide sequence which preferably consists of 5-15 amino acids and contains at least one Lys as a cleavage site for endoproteinase LysC.
- This linker preferably contains a combination of several amino acids, selected from the amino acids Gly, Thr, Ser, Ala, Pro, Asp, Glu, Arg and Lys.
- a linker is particularly preferably used in which 2-8 of these amino acids are the negatively charged amino acids Asp and / or Glu. The linker expediently ends at the C-terminal with Lys.
- 5-15 amino acids” and “2-8 of these amino acids” are to be understood such that in the case of a linker which consists of 5 amino acids, at least one amino acid is Lys and, in the preferred embodiment, 2-3 of the amino acids Asp and / or are glu.
- a linker consisting of 9 amino acids 2-8 of the amino acids can be Asp and / or Glu in the preferred embodiment.
- the 9th amino acid is Lys.
- nucleic acids encoding the fusion protein (preferably DNA) can be carried out according to the known methods as described in Sambrook, J. et al. (1989) (6).
- Streptavidin for example, as described in EP-B 0 198 015 (7) and EP-A 0 612 325 (8), can be used as streptavidin.
- Other streptavidin derivatives or fragments as described for example by Sano, T. et al., (9), are also suitable.
- a streptavidin which is truncated (shortened) at the N-terminus and / or C-terminus is preferably used as streptavidin. This prevents aggregation and proteolysis (Sano, T. et al., (9)).
- a streptavidin is preferably used which begins with amino acids 10-20 and ends with amino acids 130-140 (numbering analogously: Argarana CE. Et al., Nucl. Acids Res. 14 (1986) 1871-1882 (23)).
- a streptavidin of amino acids 16-133 or 13-139 is preferably used.
- Natriuretic peptides in the sense of the invention are peptides with natriuretic activity which are formed in the ventricle of the heart, the adrenal gland and the brain from a precursor polypeptide (prohormone) and which have a ring of 17 amino acids as structural element, which is formed by a disulfide bridge between two cysteine residues.
- Precursor polypeptides are e.g. B. the "atrial" natriuretic peptide (ANP 1-126) or cardiodilatin (CCD 1-126) and the "brain" natriuretic peptides of the B and C type.
- Preferred NP peptides are derived from the "human ⁇ atrial-natriuretic peptide" (h ⁇ ANP).
- h ⁇ ANP human ⁇ atrial-natriuretic peptide
- the C-terminal h ⁇ ANP fragments of amino acids 95-126, 99-126 and 102-126 are particularly preferred.
- the fusion proteins are produced by expressing a DNA which codes for the fusion protein in prokaryotic or eukaryotic host cells, preferably in prokaryotes.
- a DNA suitable for expression can preferably be produced synthetically. Such methods are familiar to the person skilled in the art and are described, for example, in Beattie K.L. and Fowler, R.F., Nature 352 (1991) 548-549 (33); EP-B 0 424 990 (34); Itakura, K. et al., Science 198 (1977) 1056-1063 (35).
- the nucleic acid sequence of the proteins according to the invention can expediently be modified. Such modifications are, for example:
- E.coli, Streptomyces or Bacillus are suitable as prokaryotic host organisms.
- Suitable eukaryotic host cells are, for example, yeasts such as Saccharomyces, Pichia, Hansenula and Kluyveromyces and fungi such as Aspergillus and Trichoderma.
- yeasts such as Saccharomyces, Pichia, Hansenula and Kluyveromyces
- fungi such as Aspergillus and Trichoderma.
- the prokaryotic cells are transfected in the usual way with the vector which contains the DNA coding for the fusion protein and then fermented in the usual way. After the cells have been disrupted, the protein is isolated in the customary manner and, if appropriate, purified using immobilized biotin or derivatives thereof, preferably using AfFinity chromatography.
- the protein is not expressed in soluble form and accumulates in prokaryotes in inactive form (IBs, “inelusion bodies”), it is expediently solubilized according to the processes familiar to the person skilled in the art with a denaturing agent such as guanidine hydrochloride or urea and by dilution or dialysis in a suitable buffer natured The dilution takes place in such a way that the denaturing agent is then diluted at least to such an extent that it no longer exhibits a denaturing effect
- the dilution is preferably carried out in a pulsed manner, for example by dropping the solubilizate in buffer which does not contain any denaturing agent
- Such a pulse-like dilution enables a practically simultaneous removal of the action of the denaturing agent and separation of the molecules to be naturalized. This largely avoids an undesired intermolecular interaction (aggregation) of the molecules to be naturalized.
- the naturalization takes place in the presence of naturalizing aids.
- naturalizing methods and naturalizing aids are known to the person skilled in the art and for example in US Pat. No. 5,077,392 (36), in the EP B 0 114 506 (37) and Marston, FA O, Biochem J 214 (1986) 1 - 12 (38) and Light, A, Biotechniques 3 (1985) 297 - 306 (39).
- the "inelusion bodies” are expediently for this purpose solubilized with the denaturing agent in the case of cysteine-containing peptides, if appropriate in the presence of a reducing agent, dilutes the denaturing agent to such an extent that it no longer has a denaturing effect and permits the fusion protein to fold into a state in which its protein domains can assume the natural state This state is characterized in that the disulfide bridges are natively linked in it and the fusion protein even without a high concentration The denaturing agent is then soluble and then cleaved with endoproteinase LysC
- dithiorythritol, dithiothreitol or mercaptoethanol is preferably used as the reducing agent.
- Naturation is then expediently carried out in the presence of a redox system, such as oxidized and reduced glutathione or cysteine
- the expression vector for the core-SA-URO (95-126) fusion gene with endoproteinase LysC cleavage site is based on the expression vector pSAM-CORE for core streptavidin.
- the preparation and description of the plasmid pSAM-CORE is described in WO 93/09144 ( 11) described.
- the unique Nhei restriction site located at the 3 'end was used in front of the stop codon of the core-SA gene
- DNA segment A (FIG. 1) and oligonucleotides 3 (SEQ ED NO: 5) and 4 (SEQ ID NO: 6)
- GGCCGCATGGACCGTATCGGTGCTCAGTCCGGACTGGGTTGCAACTCCTTCCGTT ACTAATGA SEQ ID NO: 5
- DNA segment B (FIG. 1) "aged” (reaction buffer: 12.5 mmol / 1 Tris-HCl, pH 7.0 and 12.5 mmol / 1 MgCl2; oligonucleotide concentration: 1 pmol / 60 ⁇ l in each case ) and the hybridization products A and B each subcloned into the polylinker region of the E. coli pUCBM21 vector (Boehringer Mannheim GmbH, Mannheim, Germany) (DNA segment A, interfaces: EcoRI and Notl; DNA segment B, interfaces: Notl and Hindlll). The DNA sequence of the two subcloned DNA segments was confirmed by means of DNA sequencing.
- the expression plasmid pSA-EK-URO for the core-SA-URO (95-126) fusion gene was then used in a three-fragment ligation from the Nhe / Notl-DNA segment A, the Notl / Hindlll-DNA segment B and the approx. 2.9 kBp long Nhel / Hindlll-pSAM-CORE vector fragment composed. After double digestion, the DNA segments A and B were isolated with the corresponding endonucleases from the corresponding pUCBM21 plasmid derivatives. The desired plasmid pSA-EK-URO was identified by restriction mapping and the DNA sequence of the linker urodilatin region was checked again by DNA sequencing.
- Example 1 To express the core-SA fusion protein, the E. coli Kl 2 strain RM82 (a methionine revertant from ED 8654, Murray, NE et al. (1977)) (14) was compared with that in Example 1 described expression plasmid pSA-EK-URO and the lacIl repressor plasmid pUBS500 (kanamycin resistance, production and description see: EP-A 0368342).
- the RM82 / pUBS500 / pSA-EK-URO cells were in DYT medium (1% (w / v) yeast extract, 1% (w / v) Bacto Tryptone (Difco, Detroit, USA) and 0.5% NaCl, with 50 mg / 1 ampicillin and 50 mg / 1 kanamycin to an optical density at 550 nm of 0.6 - 0.9 and then with IPTG (isopropyl-ß-D-thiogalactoside) (1 - 5 mmol / l final concentration After an induction phase of 4-8 hours, the cells were harvested by centrifugation and the cell pellets were washed with 25 mmol / l potassium phosphate buffer, pH 7.5.
- the cell pellets from 1 ml of centrifuged growth medium (RM82 / pUBS500 / pSA-EK-URO cells) were resuspended in 0.25 ml of 10 mmol / l phosphate buffer, pH 6.8 and 1 mmol / l EDTA and the cells were disrupted by ultrasound treatment . After centrifugation, the supernatant was mixed with 1/5 volume of 5 ⁇ SDS sample buffer (1 ⁇ SDS sample buffer: 50 mmol / l Tris-HCl, pH 6.8, 1% SDS, 1% mercaptoethanol, 10% glycerol, 0.001% bromophenol blue) .
- the insoluble cell debris fraction was resuspended in 0.3 ml lxSDS sample buffer with 6-8 M urea, the samples were incubated for 5 minutes at 95 ° C. and centrifuged. The proteins were then separated by SDS-polyacrylamide gel electrophoresis (PAGE) (Laemmli, U.K. (1970)) (15) and stained with Coomassie Brilliant Blue R dye.
- PAGE SDS-polyacrylamide gel electrophoresis
- the core-SA fusion protein synthesized in E. coli was homogeneous and was found exclusively in the insoluble cell debris fraction (IBs).
- the level of expression for the core-SA fusion protein was 30-50% based on the total E. coli protein.
- E. coli RM82 / pUBS500 / pSA-EK-URO cells 200 g (wet weight) of E. coli RM82 / pUBS500 / pSA-EK-URO cells were suspended in 1 10 0.1 mol / 1 Tris-HCl, pH 7.0 at 0 ° C., 300 mg of lysozyme were added and 20 minutes incubated at 0 ° C. The cells were then completely opened mechanically by means of high-pressure dispersion and the DNA was digested in 30 minutes at 25 ° C. by adding 2 ml of 1 mol / 1 MgCl2 and 10 mg of DNAse (Boehringer Mannheim # 154709).
- the pellet was suspended in 1 1 0.1 mol / l Tris-HCl, 20 mmol / l EDTA, pH 6.5, incubated for 30 minutes at 25 ° C. and the IB preparation was isolated by centrifugation.
- IB pellet 25 g were suspended in 200 ml of 0.1 mol / l sodium phosphate buffer, 6 mol / l guanidine-HCl, 10 mmol / l EDTA, pH 7.0 by stirring at 25 ° C. for 2 hours. The insoluble constituents were removed by centrifugation and the clear supernatant was processed further.
- the renaturation was carried out in a BioFlo II fermenter (New Brunswick Scientific Co., Inc.Edison, NJ, USA) at 16 ° C. with stirring (300 rpm) by continuously adding 200 ml of core-SA fusion protein solubilisate in 5 1 20 mmol / l sodium phosphate, pH 7.0, 5 mmol / l EDTA by means of a pump (delivery rate: 15-20 ml / hour).
- the renaturation mixture was concentrated by cross-flow filtration in a Minisette (membrane type: Nova K10) from Filtron (Karlstein, Germany) and dialyzed against a desired buffer if necessary to remove guanidine-HCl.
- Minisette membrane type: Nova K10
- Filtron Karlstein, Germany
- the core-SA fusion protein was purified directly from the filtered and concentrated renaturate by affinity chromatography on iminobiotin-Sepharose
- the gel suspension was incubated at room temperature with gentle shaking overnight and then on a frit with 5 1 10 mmol / l potassium phosphate buffer, pH 7.5 with 150 mmol / l NaCl and 20% DMSO, 3 1 deionized water and 3 1 10 mmol / l potassium phosphate buffer, pH 7.5 with 150 mmol / l NaCl
- a column was filled with exactly 1 ml iminobiotin-Sepharose 4B and equilibrated with 50 mmol / l ethanolamine buffer, pH 9.5 with 0.5 mmol / l NaCl. Then a core-SA solution with a concentration was added of 1 mg / ml applied in equilibration buffer
- the loading capacity / ml affinity gel (30-40 mg core-SA / ml gel) was determined by measuring the absorption at 280 nm in the eluate and determining the application volume.
- the core-SA-EK-URO fusion protein was in a concentration of 0.3 to 3 mg / ml and a substrate / protease ratio of 1: 1000 to 1: 25000 (endoproteinase LysC from Lysobacter enzymogenes, sequencing grade; Boehringer Mannheim , Mannheim, Germany) in 50 mmol / I Tris-HCl, pH 8.0 at 30 to 35 ° C and the time course of the enzymatic cleavage was analyzed by analytical reversed phase HPLC (see Example 8). For this purpose, samples (10 to 100 ⁇ l) were taken at intervals of 1 to 3 hours from the reaction mixture over a period of 6 to 24 hours.
- the enzymatically released peptide can be further purified using chromatographic methods known to the person skilled in the art.
- the core-SA carrier protein can be separated from the cleavage mixture by negative chromatography on iminobiotin-Sepharose, as described in Example 5 for the core-SA fusion protein
- the reaction mixture is adjusted to a pH of 9 to 9.5 with ethanolamine and the core-SA carrier protein and uncleaved core-SA fusion protein are separated off by affinity binding to iminobiotin.
- the sample volume was 10-100 ⁇ l, corresponding to 1-100
- the detection was carried out with a UV detector at 220 nm. Chromatography was carried out at a flow rate of 0.5 ml / min.
- the identity and purity of the purified peptide can be determined, for example, by mass spectroscopy (PD-MS and laser desorption spectroscopy), analytical reversed phase HPLC, isoelectric focusing (Bark, JE et al, J Forensic Sei Soc 16 (1976) 115-120 (42) , SDS PAGE (Laemmli, UK, Nature 227 (1970) 680-685 (43)) and capillary electrophoresis, in comparison with a chemically produced standard
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU71300/96A AU7130096A (en) | 1995-09-23 | 1996-09-17 | Process for producing natriuretic peptides via streptavidine fusion proteins |
JP9512381A JPH11511333A (ja) | 1995-09-23 | 1996-09-17 | ストレプトアビジン融合タンパク質によるナトリウム排泄増加性ペプチドを生産するための方法 |
EP96932542A EP0851930A1 (de) | 1995-09-23 | 1996-09-17 | Verfahren zur herstellung von natriuretischen peptiden über streptavidin-fusionsproteine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1995135445 DE19535445A1 (de) | 1995-09-23 | 1995-09-23 | Verfahren zur Herstellung von natriuretischen Peptiden über Streptavidin-Fusionsproteine |
DE19535445.1 | 1995-09-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997011186A1 true WO1997011186A1 (de) | 1997-03-27 |
Family
ID=7773008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/004061 WO1997011186A1 (de) | 1995-09-23 | 1996-09-17 | Verfahren zur herstellung von natriuretischen peptiden über streptavidin-fusionsproteine |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0851930A1 (de) |
JP (1) | JPH11511333A (de) |
AU (1) | AU7130096A (de) |
CA (1) | CA2232841A1 (de) |
DE (1) | DE19535445A1 (de) |
WO (1) | WO1997011186A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004106525A1 (fr) * | 2003-06-03 | 2004-12-09 | Shanghai Centre Of Research & Development Of New Drugs | Proteine de fusion pouvant etre exprimee tres efficacement et son procede de production |
EP1865059A1 (de) | 2001-03-12 | 2007-12-12 | Japan Tobacco, Inc. | Neues Protein, dafür kodierendes Gen und Verwendungsverfahren dafür |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4656493B2 (ja) * | 2002-11-20 | 2011-03-23 | ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー | 部分的proANPペプチドを同定するためのサンドイッチイムノアッセイ |
US20080181903A1 (en) * | 2006-12-21 | 2008-07-31 | Pdl Biopharma, Inc. | Conjugate of natriuretic peptide and antibody constant region |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986002077A1 (en) * | 1984-10-02 | 1986-04-10 | Meade Harry M | Production of streptavidin-like polypeptides |
GB2180539A (en) * | 1985-07-24 | 1987-04-01 | Glaxo Group Ltd | Microbiological products |
WO1988006596A1 (en) * | 1987-03-02 | 1988-09-07 | Bissendorf Peptide Gmbh | New cardiodilatin fragment, process for preparing same and use thereof |
WO1989003422A1 (en) * | 1987-10-08 | 1989-04-20 | British Bio-Technology Limited | Synthetic gene |
EP0440311A1 (de) * | 1985-06-20 | 1991-08-07 | Fujisawa Pharmaceutical Co., Ltd. | Herstellungsverfahren für menschliches alpha-Atrio-natriuretisches Polypeptid |
EP0528686A2 (de) * | 1991-08-19 | 1993-02-24 | Suntory Limited | Verfahren zur Herstellung von Peptiden |
-
1995
- 1995-09-23 DE DE1995135445 patent/DE19535445A1/de not_active Ceased
-
1996
- 1996-09-17 CA CA 2232841 patent/CA2232841A1/en not_active Abandoned
- 1996-09-17 JP JP9512381A patent/JPH11511333A/ja active Pending
- 1996-09-17 EP EP96932542A patent/EP0851930A1/de not_active Withdrawn
- 1996-09-17 AU AU71300/96A patent/AU7130096A/en not_active Abandoned
- 1996-09-17 WO PCT/EP1996/004061 patent/WO1997011186A1/de not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986002077A1 (en) * | 1984-10-02 | 1986-04-10 | Meade Harry M | Production of streptavidin-like polypeptides |
EP0440311A1 (de) * | 1985-06-20 | 1991-08-07 | Fujisawa Pharmaceutical Co., Ltd. | Herstellungsverfahren für menschliches alpha-Atrio-natriuretisches Polypeptid |
GB2180539A (en) * | 1985-07-24 | 1987-04-01 | Glaxo Group Ltd | Microbiological products |
WO1988006596A1 (en) * | 1987-03-02 | 1988-09-07 | Bissendorf Peptide Gmbh | New cardiodilatin fragment, process for preparing same and use thereof |
WO1989003422A1 (en) * | 1987-10-08 | 1989-04-20 | British Bio-Technology Limited | Synthetic gene |
EP0528686A2 (de) * | 1991-08-19 | 1993-02-24 | Suntory Limited | Verfahren zur Herstellung von Peptiden |
Non-Patent Citations (2)
Title |
---|
M. LENNICK ET AL: "High-level expression of alpha-human atrial natriuretic peptide from multiple joined genes in Escherichia coli", GENE, vol. 61, 1987, pages 103 - 112, XP002022297 * |
Y. SAITO ET AL: "Bacterial synthesis of recombinant alpha human atrial natriuretic polypeptide", JOURNAL OF BIOCHEMISTRY, vol. 102, no. 1, July 1987 (1987-07-01), pages 111 - 122, XP002022296 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1865059A1 (de) | 2001-03-12 | 2007-12-12 | Japan Tobacco, Inc. | Neues Protein, dafür kodierendes Gen und Verwendungsverfahren dafür |
US7713531B2 (en) | 2001-03-12 | 2010-05-11 | Japan Tobacco, Inc. | Protein, a gene encoding therefor and a method of using the same |
US7776333B2 (en) | 2001-03-12 | 2010-08-17 | Japan Tobacco Inc. | Protein, a genes encoding therefor and a method of using the same |
US7855282B2 (en) | 2001-03-12 | 2010-12-21 | Japan Tobacco Inc. | Protein, a gene encoding therefor and a method of using the same |
US7989610B2 (en) | 2001-03-12 | 2011-08-02 | Japan Tobacco Inc | Protein, a gene encoding therefor and a method of using the same |
WO2004106525A1 (fr) * | 2003-06-03 | 2004-12-09 | Shanghai Centre Of Research & Development Of New Drugs | Proteine de fusion pouvant etre exprimee tres efficacement et son procede de production |
CN1298742C (zh) * | 2003-06-03 | 2007-02-07 | 上海新药研究开发中心 | 一种适合于高效表达的融合蛋白及其生产方法 |
US7795384B2 (en) | 2003-06-03 | 2010-09-14 | Shanghai Centre Of Research & Development Of New Drugs | Fusion protein suitable for high efficiency expression and the production method thereof |
Also Published As
Publication number | Publication date |
---|---|
DE19535445A1 (de) | 1997-03-27 |
AU7130096A (en) | 1997-04-09 |
JPH11511333A (ja) | 1999-10-05 |
EP0851930A1 (de) | 1998-07-08 |
CA2232841A1 (en) | 1997-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1997018314A1 (de) | Verfahren zur herstellung von peptiden über streptavidin-fusionsproteine | |
JP3054192B2 (ja) | 副甲状腺ホルモンの製造のための組換えdna法 | |
DE69434083T2 (de) | Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird | |
DE69233008T2 (de) | Fusionierung von Peptiden und Proteinen mit Thioredoxin und thioredoxin-ähnlichen Molekülen | |
EP0305500B1 (de) | Verfahren zur reinigung von rekombinanten polypeptiden | |
US5322930A (en) | Expression of recombinant polypeptides with improved purification | |
US7105638B1 (en) | Product and process for the production, isolation, and purification of recombinant polypeptide | |
EP1931705B1 (de) | Verfahren zur amidierung von polypeptiden mit c-terminalen basischen aminosäuren unter verwendung spezifischer endoproteasen | |
DE3882593T2 (de) | Polypeptid und dessen Herstellung. | |
EP0229998B1 (de) | Fusionsproteine mit eukaryotischem Ballastanteil | |
EP1819729A2 (de) | Verfahren zur herstellung von carboxy-terminal amidierten peptiden | |
DD291093A5 (de) | Recombinierende dna-sequenzen und ihr verfahren zur herstellung des menschlichen proapolipoprotein a-i | |
AU665034B2 (en) | Production of human parathyroid hormone from microorganisms | |
DE69930938T2 (de) | Verfahren zur herstellung eines peptids mit einem pi grösser als 8 oder kleiner als 5 | |
EP1066328A1 (de) | Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthältund dessen anwendung zur insulinproduktion | |
WO1997011186A1 (de) | Verfahren zur herstellung von natriuretischen peptiden über streptavidin-fusionsproteine | |
JP2637392B2 (ja) | 遺伝子操作による生物活性β−NGFの生産方法 | |
EP0453456B1 (de) | Pdgf-a, pdgf-aa, pdgf-ab, herstellungsverfahren und sie enthaltende arzneimittel | |
US20020164712A1 (en) | Chimeric protein containing an intramolecular chaperone-like sequence | |
DE3811921A1 (de) | Verfahren zur herstellung von proteinen, die n-terminal mit prolin beginnen | |
JP2994017B2 (ja) | ポリペプチド | |
JP2002533072A (ja) | β−リポトロピンおよび他のペプチドの組換え合成 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996932542 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2232841 Country of ref document: CA Ref country code: JP Ref document number: 1997 512381 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2232841 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996932542 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996932542 Country of ref document: EP |